Flagship Pioneering raises $3.6 billion to fuel critical breakthroughs in human health and sustainability. This expanded capital pool will accelerate the impact of original science and the creation and development of an estimated 25 breakthrough companies in human health, sustainability, and artificial intelligence. Hear from Flagship Founder and CEO Noubar Afeyan about how we're taking #BiggerLeaps by leveraging the power of generative AI, forging novel partnerships with pharma to speed drug development, expanding globally, and promoting and hiring top talent to our leadership ranks. Read the full press release: https://bit.ly/4eQfx05
Flagship Pioneering
Biotechnology Research
Cambridge, MA 94,121 followers
We are a biotechnology company that invents and builds platform companies that change the world.
About us
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
- Website
-
http://www.flagshippioneering.com
External link for Flagship Pioneering
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2000
- Specialties
- life sciences, biotech, therapeutics, diagnostics, sustainability, climate change, artificial intelligence, machine learning, agtech, medicines, therapeutics, biology, entrepreneurship, biotechnology, science, innovation, and ventures
Locations
-
Primary
55 Cambridge Parkway
Suite 800E
Cambridge, MA 02142, US
Employees at Flagship Pioneering
-
Karim Lakhani
Professor Harvard Business School | Chair D^3 Institute at Harvard | Board Member, Mozilla Corporation & VideaHealth | Academic Partner, Flagship…
-
Venu Nagali
Strategy, Business Development & Finance Executive ✦ Increase Enterprise Value through Innovative Strategies and Building Results-Producing Teams
-
Susan Vidal
Strategic HR Leader & Employee Retention Evangelist
-
David Khougazian
Growth Partner at Flagship Pioneering
Updates
-
#FlagshipFounded YourBio Health announces partnership with RecoveryTrek to offer a more convenient and painless way for substance use disorder patients to access alcohol biomarker testing.
YourBio Health and RecoveryTrek Partner to Revolutionize Alcohol Biomarker Testing for Substance Use Disorder Patients Today YourBio Health announced a partnership with RecoveryTrek to provide a more convenient and painless way for substance use disorder patients to access phosphatidylethanol (PEth) alcohol biomarker testing. This innovative partnership combines RecoveryTrek's PROOF™ virtual remote collection and testing solution with YourBio Health's TAP® Micro Select device. Here's what this means for patients: 🔹 Easier and more convenient testing: No more visits to clinics or labs! Patients can now receive a PROOF™ kit and conduct their tests remotely, anytime, anywhere. 🔹 Virtually painless experience: The TAP® Micro Select device offers a gentler blood sampling method compared to traditional methods, leading to higher compliance rates. 🔹 Improved control over recovery: RecoveryTrek's PROOF™ app provides step-by-step instructions and guidance, empowering patients to take charge of their health journey. This partnership is a major step forward in transforming recovery monitoring and empowering individuals in their journey towards wellness. 🔗 Read the full article here: https://lnkd.in/ecSA2WQh #RecoveryTrek #YourBioHealth #SubstanceUseDisorder #HealthTech #Telehealth
-
🎙 Michelle Werner, Flagship CEO-Partner & CEO of #FlagshipFounded Alltrna chats with Kaitlin Dailey about Alltrna’s tRNA platform to decipher tRNA biology and pioneer novel therapeutics to treat thousands of diseases in this RNA Leaders podcast episode. Tune in ⬇ For more on how Alltrna's engineered tRNAs allow the company to look across different diseases to fundamentally think differently about potential treatments for genetic conditions, tune in to this CEO chat with Michelle: https://bit.ly/3vqkkmB
What will it take to advance the first tRNA medicines into the clinic? 🎙️ Tune in to this podcast with RNA Leaders to hear our CEO Michelle Werner share her thoughts about the next steps to support the development of this unique therapeutic modality, which has the potential to scale and accelerate genetic medicines for rare diseases. Michelle also previews what she plans to present at this year's conference in September. Listen here: https://lnkd.in/gPqgNu3R #RNALeaders #RNALeaders24 #tRNA #RNA #tRNAmedicines #tRNAbiology #rarediseases #geneticmedicines #programmablemedicines #machinelearning #AI #StopCodonDisease
-
Flagship Pioneering reposted this
“Because of climate change and our growing global population, we need to have radical solutions as fast as possible. With AI-powered Predictive Design and Multiplex Gene Editing, this can be done.” That’s Emily Negrin, our VP of Corporate Affairs, speaking today at the U.S. Mission to the United Nations. She joined Ambassador Linda Thomas-Greenfield, Ambassador Michele Sison and industry experts to discuss how Inari and others in the private sector are working to combat the growing threat to food security driven by climate change. With the ability to design seeds that meet the world’s needs, Inari is uniquely positioned to help ensure food security for a rapidly growing global population, while better caring for our planet and improving farmer well-being through economically sustainable solutions. Thank you to Ambassadors Thomas-Greenfield and Sison for welcoming us to today’s enlightening conversation.
-
Thank you, NYSE, for celebrating our most recent capital raise! For more on how this raise will fuel the creation and growth of breakthrough companies in human health, sustainability, and artificial intelligence, watch Noubar Afeyan, Flagship Founder & CEO, as he discusses Flagship’s recent advances including key partnerships, expanding our global footprint, and assembling top talent: https://bit.ly/4bENCgK
-
Flagship Founder & CEO Noubar Afeyan chats with Brad Loncar on BiotechTV about our recent capital raise, how we’re building breakthrough multiproduct companies in human health and sustainability, and how we’re partnering with pharma to speed drug discovery as well as other collaborators across the globe to unlock opportunity in the life sciences. Read our announcement: https://bit.ly/4eQfx05
𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐍𝐞𝐰𝐬: Flagship Pioneering today announced a $3.6B capital raise in its Fund VIII and side funds. Founder & CEO Noubar Afeyan discusses the details. He describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market, taking Flagship global, AI, and more. Full video: https://lnkd.in/gkwCTRWp BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Oliver Barnes of the Financial Times writes about our most recent capital raise and how we’re harnessing AI to develop breakthrough innovations in human health and sustainability. Read the full article here: https://lnkd.in/eeSb8eDY
NEW: Flagship Pioneering, the venture capital fund that launched Moderna, is planning to create a spree of new biotechs harnessing generative artificial intelligence to power drug discovery after securing $3.6bn in funding from its financial backers. As part of its latest fundraise, the venture firm raised $2.6bn for its eighth fund and $1bn to deploy across parallel funds, which will invest in specific sectors, such as certain diagnostics or therapeutics. Flagship is also likely to raise extra money for its eighth fund later this year, helping it meet a target of $3bn for the investment vehicle. Much of the investments from Flagship’s fund VIII will be focused on platforms that use AI in novel ways to develop drugs, according to Noubar Afeyan, who founded Flagship in 2000. “Each of the pools of capital we raise supports around 25 companies; I wouldn’t be surprised if the majority of [the companies in fund VIII] are but for AI we wouldn’t do them,” said Afeyan. The close of Flagship’s latest raise is a bullish sign for venture investment in biotech, which has been trying to recover following a downturn caused by the end of a pandemic-inspired boom in addition to a series of interest rate hikes. https://on.ft.com/3S0S1DI
-
"Nearly 25 years into our pioneering journey at Flagship, we are just getting started,” shares Flagship Founder & CEO Noubar Afeyan on the heels of our capital pool raise of $3.6 billion. Hear from Noubar on how these resources will advance our work and what drives the Flagship team to pioneer new scientific platforms, and build and scale companies around them. #WeAreFlagship ⬇
“What’s It All For?”
Noubar Afeyan on LinkedIn
-
Congratulations to the team at #FlagshipFounded Empress Therapeutics on being recognized by Nature Portfolio for the breakthrough principle of using co-evolution to guide the discovery of drugs by finding biologically active small molecules encoded in human metagenomic data.
We are excited to share that Nature Biotechnology highlighted Empress Therapeutics as a top startup! We were recognized for the breakthrough principle of using co-evolution to guide the discovery of drugs by finding biologically active small molecules encoded in human metagenomic data. Empress scientists estimate that 10^24 possible chemical compounds have been made and tested inside the bodies of humans by co-evolved microbial chemists – greater than any in silico or physical library, and with the added advantages of built-in human relevance and compatibility. We analyze genes encoding biosynthetic pathways that make these compounds to draw associations with health or disease, then use AI and synthetic biology to generate drug leads from gene data. The impact? Predictability and speed in small molecule drug discovery. Read the article to learn more: https://lnkd.in/gsZ-kPqc #FlagshipFounded #Chemilogics #smallmolecule #drugdiscovery #AI #synbio
Editor’s pick: Empress Therapeutics - Nature Biotechnology
nature.com
-
Learn more about our approach to innovation, building companies, and pioneering the future of human health, sustainability, and AI in this Boston Globe Media piece by Scott Kirsner on Flagship and our recent capital raise of $3.6 billion: https://lnkd.in/eqgrdgzN
How Flagship Pioneering built its unique success in life sciences - The Boston Globe
bostonglobe.com